MEDICATIONS DEVELOPMENT FOR STIMULANT DEPENDENCE (MDS)

RELEASE DATE:  January 30, 2004

NOTICE:  NOT-DA-04-022

RFP AVAILABLE:  N01DA-4-8845

National Institute on Drug Abuse (NIDA)
 (http://www.nida.nih.gov/)

The National Institute on Drug Abuse (NIDA) is soliciting 
proposals from qualified investigational sites having the 
capability to conduct Phase II or Phase III clinical trials of 
potential treatment medications, both investigational and 
marketed, for treatment of (1) stimulant abuse and dependence 
(i.e., cocaine, or methamphetamine), (2) codependence with 
alcohol and stimulants, (3) nicotine dependence. Specifically, 
contractors will conduct clinical trials to investigate the 
efficacy and safety of medications for the treatment of stimulant 
addiction, codependence with stimulants and alcohol, and nicotine 
under the current Food and Drug Administration regulations and 
ICH guidelines. NIDA will supply the study protocol and database 
management services. The offeror shall provide all other 
necessary services to conduct clinical trials. In order to handle 
substances under the Controlled Substances Act of 1970, it is 
mandatory that offerors possess a DEA Research Registration for 
Schedules II to V and demonstrate the capability to obtain a DEA 
registration for Schedule I controlled substances. We anticipate 
multiple awards up to ten, five-year, task order type contracts 
as a result of this solicitation. RFP No. NO1DA-4-8845 will be 
available electronically on or about February 13, 2004. You can 
access the RFP through the FedBizOpps (URL: 
http://www.fedbizopps.gov or through the NIDA website at the 
following address: (URL: 
http://www.nida.nih.gov/RFP/RFPList.html). Please note that NIDA 
will streamline the RFP for this acquisition to include only the 
Work Statement, Deliverables, Reporting Requirements, Special 
Requirements, Mandatory Qualifications, Technical Evaluation 
Criteria, and other necessary Proposal Preparation Instructions. 
However, NIDA will make all information required for the 
submission of an offer will be accessible through the streamlined 
electronic RFP package. Response to the RFP will be due on or 
about April 13, 2004. NIDA will consider proposals submitted by 
any responsible offeror. This advertisement does not commit the 
Government to award a contract. 

Point of Contact:

Jordan T. Pulaski, Contract Specialist
Contracts Management Branch, OPRM
National Institute on Drug Abuse, NIH
(301) 443-6677; Fax: (301) 443-7595

Return to Volume Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.